Literature DB >> 18851875

Allogeneic transplantation successfully corrects immune defects, but not susceptibility to colitis, in a patient with nuclear factor-kappaB essential modulator deficiency.

Sung-Yun Pai1, Ofer Levy, Haifa H Jabara, Jonathan N Glickman, Liat Stoler-Barak, Jessica Sachs, Samuel Nurko, Jordan S Orange, Raif S Geha.   

Abstract

BACKGROUND: Boys with X-linked ectodermal dysplasia and immunodeficiency caused by mutations of nuclear factor-kappaB essential modulator have defects in innate and adaptive immunity, and some have colitis.
OBJECTIVE: We sought to determine whether curing the immune defect in such patients by means of allogeneic hematopoietic stem cell transplantation abolishes the susceptibility to colitis.
METHODS: A boy with X-linked hypohydrotic ectodermal dysplasia with immunodeficiency underwent allogeneic transplantation from a matched unaffected sibling identified by means of preimplantation genetic diagnosis. Toll-like receptor (TLR) function was assessed by measuring TLR agonist-induced cytokine production in whole blood tested in vitro. B-cell proliferation was measured by means of tritiated thymidine incorporation. Natural killer cell function was examined in PBMCs by means of K562 target cell lysis. Colitis severity was assessed clinically based on corticosteroid requirement and histology of large intestinal biopsy specimens.
RESULTS: Defects in cytokine production in response to TLR agonists, CD40-mediated proliferation, and natural killer cell cytotoxicity were all corrected after hematopoietic stem cell transplantation. Despite successful hematopoietic and immune reconstitution, the patient continued to have flares of colitis, often associated with bacterial infection.
CONCLUSIONS: Our findings strongly suggest that nuclear factor-kappaB essential modulator deficiency intrinsic to the intestinal epithelium is sufficient to predispose to colitis, despite robust correction of immune defects.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18851875      PMCID: PMC6141239          DOI: 10.1016/j.jaci.2008.08.026

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  18 in total

1.  PIDD mediates NF-kappaB activation in response to DNA damage.

Authors:  Sophie Janssens; Antoine Tinel; Saskia Lippens; Jürg Tschopp
Journal:  Cell       Date:  2005-12-16       Impact factor: 41.582

Review 2.  Innate immune recognition at the epithelial barrier drives adaptive immunity: APCs take the back seat.

Authors:  Jörg H Fritz; Lionel Le Bourhis; Joao Gamelas Magalhaes; Dana J Philpott
Journal:  Trends Immunol       Date:  2007-11-28       Impact factor: 16.687

3.  Molecular linkage between the kinase ATM and NF-kappaB signaling in response to genotoxic stimuli.

Authors:  Zhao-Hui Wu; Yuling Shi; Randal S Tibbetts; Shigeki Miyamoto
Journal:  Science       Date:  2006-02-24       Impact factor: 47.728

4.  Correction of immunodeficiency associated with NEMO mutation by umbilical cord blood transplantation using a reduced-intensity conditioning regimen.

Authors:  C Tono; Y Takahashi; K Terui; S Sasaki; T Kamio; S Tandai; T Sato; K Kudo; T Toki; N Tachibana; T Yoshioka; T Nakahata; T Morio; R Nishikomori; E Ito
Journal:  Bone Marrow Transplant       Date:  2007-04-09       Impact factor: 5.483

Review 5.  Signals from within: the DNA-damage-induced NF-kappaB response.

Authors:  S Janssens; J Tschopp
Journal:  Cell Death Differ       Date:  2006-05       Impact factor: 15.828

Review 6.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

Authors:  Tim Bongartz; Alex J Sutton; Michael J Sweeting; Iain Buchan; Eric L Matteson; Victor Montori
Journal:  JAMA       Date:  2006-05-17       Impact factor: 56.272

7.  Deficient natural killer cell cytotoxicity in patients with IKK-gamma/NEMO mutations.

Authors:  Jordan S Orange; Scott R Brodeur; Ashish Jain; Francisco A Bonilla; Lynda C Schneider; Roberto Kretschmer; Samuel Nurko; Wendy L Rasmussen; Julia R Köhler; Stephen E Gellis; Betsy M Ferguson; Jack L Strominger; Jonathan Zonana; Narayanaswamy Ramesh; Zuhair K Ballas; Raif S Geha
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

8.  Selective impairment of TLR-mediated innate immunity in human newborns: neonatal blood plasma reduces monocyte TNF-alpha induction by bacterial lipopeptides, lipopolysaccharide, and imiquimod, but preserves the response to R-848.

Authors:  Ofer Levy; Kol A Zarember; Rene M Roy; Colette Cywes; Paul J Godowski; Michael R Wessels
Journal:  J Immunol       Date:  2004-10-01       Impact factor: 5.422

9.  The presentation and natural history of immunodeficiency caused by nuclear factor kappaB essential modulator mutation.

Authors:  Jordan S Orange; Ashish Jain; Zuhair K Ballas; Lynda C Schneider; Raif S Geha; Francisco A Bonilla
Journal:  J Allergy Clin Immunol       Date:  2004-04       Impact factor: 10.793

10.  Epithelial NEMO links innate immunity to chronic intestinal inflammation.

Authors:  Arianna Nenci; Christoph Becker; Andy Wullaert; Ralph Gareus; Geert van Loo; Silvio Danese; Marion Huth; Alexei Nikolaev; Clemens Neufert; Blair Madison; Deborah Gumucio; Markus F Neurath; Manolis Pasparakis
Journal:  Nature       Date:  2007-03-14       Impact factor: 49.962

View more
  20 in total

1.  Disseminated BCG infection mimicking metastatic nasopharyngeal carcinoma in an immunodeficient child with a novel hypomorphic NEMO mutation.

Authors:  Masaru Imamura; Tomoki Kawai; Satoshi Okada; Kazushi Izawa; Takayuki Takachi; Haruko Iwabuchi; Sakiko Yoshida; Ryosuke Hosokai; Hirokazu Kanegane; Tatsuo Yamamoto; Hajime Umezu; Ryuta Nishikomori; Toshio Heike; Makoto Uchiyama; Chihaya Imai
Journal:  J Clin Immunol       Date:  2011-07-14       Impact factor: 8.317

2.  Successful hematopoietic cell transplantation in patients with unique NF-κB essential modulator (NEMO) mutations.

Authors:  J K Abbott; R R Quinones; M T de la Morena; E W Gelfand
Journal:  Bone Marrow Transplant       Date:  2014-07-28       Impact factor: 5.483

Review 3.  Update on the hyper immunoglobulin M syndromes.

Authors:  E Graham Davies; Adrian J Thrasher
Journal:  Br J Haematol       Date:  2010-02-23       Impact factor: 6.998

4.  XL-EDA-ID Presenting with Congenital Duodenal Atresia and Perforations.

Authors:  Yusuke Mitani; Taizo Wada; Yusuke Matsuda; Seisho Sakai; Akihiro Yachie
Journal:  J Clin Immunol       Date:  2018-08-27       Impact factor: 8.317

Review 5.  Infectious diseases in patients with IRAK-4, MyD88, NEMO, or IκBα deficiency.

Authors:  Capucine Picard; Jean-Laurent Casanova; Anne Puel
Journal:  Clin Microbiol Rev       Date:  2011-07       Impact factor: 26.132

Review 6.  Prospects for modulating the CD40/CD40L pathway in the therapy of the hyper-IgM syndrome.

Authors:  Xiangxue Meng; Bin Yang; Wen-Chen Suen
Journal:  Innate Immun       Date:  2017-11-13       Impact factor: 2.680

Review 7.  The hyper IgM syndromes.

Authors:  Nashmia Qamar; Ramsay L Fuleihan
Journal:  Clin Rev Allergy Immunol       Date:  2014-04       Impact factor: 8.667

Review 8.  Advances in basic and clinical immunology in 2008.

Authors:  Javier Chinen; William T Shearer
Journal:  J Allergy Clin Immunol       Date:  2009-02       Impact factor: 10.793

9.  A novel gain-of-function IKBA mutation underlies ectodermal dysplasia with immunodeficiency and polyendocrinopathy.

Authors:  Lena F Schimke; Nikolaus Rieber; Stacey Rylaarsdam; Otávio Cabral-Marques; Nicholas Hubbard; Anne Puel; Laura Kallmann; Stephanie Anover Sombke; Gundula Notheis; Hans-Peter Schwarz; Birgit Kammer; Tomas Hökfelt; Reinald Repp; Capucine Picard; Jean-Laurent Casanova; Bernd H Belohradsky; Michael H Albert; Hans D Ochs; Ellen D Renner; Troy R Torgerson
Journal:  J Clin Immunol       Date:  2013-05-25       Impact factor: 8.317

Review 10.  Regulation of tissue homeostasis by NF-kappaB signalling: implications for inflammatory diseases.

Authors:  Manolis Pasparakis
Journal:  Nat Rev Immunol       Date:  2009-11       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.